Forecasted demand for Current and New ARV medicines in low and middle income countries, 2015-2025

WHO/MPP forecast excerpts from the Joint WHO/UNAIDS Meeting with Manufacturers and Partners on Global ARV Demand Forecast March 8-9, 2016

Medicines Patent Pool
World Health Organization
• New drugs in the pipeline – some approved, some expected soon

• Licences for these drugs will stimulate generic manufacturing, appropriate formulations such as FDCs, increased availability and affordable prices

• However, for full and early benefit, all public health actors need to be informed, prepared and aligned
  • Generics manufacturers need to understand volumes required and when
  • Policy makers need to understand when generics would be available and in what formulations
  • Procurement agents need to understand pricing and timing
  • SRA and country level registration need to be expedited to accelerate access in the countries

• Forecasts are a key element to start and prioritise the process of putting a new drug on the market as well as answering some of the questions above
Key Variables Considered

- Date of generic availability
- Price differential between new and similar existing drugs
- WHO guidelines
  - What may be on the guidelines
  - Which line of treatment may each drug be recommended in
  - When may this recommendation happen
  - Availability of data in special populations (TB, pregnancy)
- National guidelines
FORECAST FOR ADULT / ADOLESCENT USE
High Level Assumptions

• Date of introduction in market:
  • DTG 50mg: Q4-2017
  • DTG FDCs: Q3-2018
  • TAF FDCs: Q1-2019

• Price:
  • At launch, DTG & TAF priced at par with EFV & TDF respectively
  • Future pricing based on historical price erosion trends

• Positive study results for DTG and TAF in special populations
  • Including drug-drug interaction of TAF with rifampicin

• WHO guidelines recommend new products first as alternate and then as preferred regimens

• New products placed on national guidelines within one year from WHO guidelines
Millions of Adults Treated in WHO/MPP* forecasts

*WHO/MPP assumes total PLHIV treated per UNAIDS fast track report
Percent of adults on **first line** treatment taking TAF, TDF and AZT

<table>
<thead>
<tr>
<th>Year</th>
<th>AZT</th>
<th>TDF</th>
<th>TAF</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>22%</td>
<td>76%</td>
<td>0%</td>
</tr>
<tr>
<td>2016</td>
<td>16%</td>
<td>81%</td>
<td>0%</td>
</tr>
<tr>
<td>2017</td>
<td>9%</td>
<td>88%</td>
<td>2%</td>
</tr>
<tr>
<td>2018</td>
<td>7%</td>
<td>90%</td>
<td>4%</td>
</tr>
<tr>
<td>2019</td>
<td>4%</td>
<td>93%</td>
<td>2%</td>
</tr>
<tr>
<td>2020</td>
<td>3%</td>
<td>92%</td>
<td>8%</td>
</tr>
<tr>
<td>2021</td>
<td>3%</td>
<td>90%</td>
<td>15%</td>
</tr>
<tr>
<td>2022</td>
<td>1%</td>
<td>85%</td>
<td>25%</td>
</tr>
<tr>
<td>2023</td>
<td>1%</td>
<td>81%</td>
<td>31%</td>
</tr>
<tr>
<td>2024</td>
<td>1%</td>
<td>71%</td>
<td></td>
</tr>
<tr>
<td>2025</td>
<td>1%</td>
<td>65%</td>
<td></td>
</tr>
</tbody>
</table>

- TDF is the clear market leader currently and continues to be so in the near future.
- At launch, TAF price is assumed to be at par with TDF, however, our model assumes a conservative uptake due to lack of clinical data and its potential interaction with rifampicin:
  - The TAF uptake picks up in later years, once such information is available, reaching 31% patients in first-line.
- We assume AZT usage follows WHO Guidelines and continues to fall to negligible share by 2019 and tenofovir in both its forms takes over the market for first line nucleosides.

**World Health Organization**
With the WHO Guidelines recommendation of EFV as a preferred regimen, the market share of NVP declines to reach zero by 2020.

EFV gains 100% of the market share from NVP decline till the introduction of DTG.

DTG, when introduced, is assumed to be priced at par with EFV.

- We assume DTG rapidly takes market share of first-line treatment from both NVP as well as EFV.
- The uptake is slower in the initial years due to non-availability of FDCs, however, from 2019 onwards, the uptake increases substantially, reaching 57% of total first-line market.
We assume a higher uptake of AZT in second-line treatment, since most patients are assumed to be using tenofovir in first line.

We also assume that TAF would be taking some market share from TDF, but the total market of tenofovir is small.

DTG

- Is not recommended in the current WHO guidelines in second line.
- However, the assumption for uptake is that patients who have not used DTG in first line would be able to do so in second line.
- The uptake is much more conservative than for first-line use, and reaches 30% patients by 2025.
Percent of adults on second line treatment taking LPV, ATV and DRV

- ATV is assumed to increase its market share in second-line due to
  - Availability of multiple generics
  - Price erosion due to competition
  - Once daily regimen
- LPV market share will thus decline in the coming years, with ATV eating into its market
- The role of DRV is very limited, as its price as well as large pill size are handicaps compared to ATV
Salvage treatment in adults

Usage in Resistant Patients: 2015
N = 26,000

Usage in Resistant Patients: 2025
N = 500,000

• The main change between 2015 and 2025 in salvage treatment is the number of patients, which increase from 26,000 currently to 0.5 million in 2025
• The mix of ARVs used does not change much except DTG will take market share from RAL, which is the other integrase inhibitor
## ARV use in 2020 and 2025 - Million People by Active Ingredient

<table>
<thead>
<tr>
<th>API</th>
<th>2020</th>
<th>2025</th>
</tr>
</thead>
<tbody>
<tr>
<td>TAF</td>
<td>0.5</td>
<td>7.9</td>
</tr>
<tr>
<td>TDF</td>
<td>20.2</td>
<td>16.3</td>
</tr>
<tr>
<td>AZT</td>
<td>2.4</td>
<td>2.2</td>
</tr>
<tr>
<td>NVP</td>
<td>2.2</td>
<td>0.0</td>
</tr>
<tr>
<td>EFV</td>
<td>16.3</td>
<td>10.0</td>
</tr>
<tr>
<td>LPV</td>
<td>1.3</td>
<td>0.9</td>
</tr>
<tr>
<td>ATV</td>
<td>1.4</td>
<td>2.3</td>
</tr>
<tr>
<td>DRV</td>
<td>0.0</td>
<td>0.2</td>
</tr>
<tr>
<td>DTG</td>
<td>4.9</td>
<td>14.8</td>
</tr>
<tr>
<td>RAL</td>
<td>0.0</td>
<td>0.1</td>
</tr>
</tbody>
</table>

*API for all formulations included*
ARV use in 2025 - Million People by Active Ingredient

Number of PLHIV (mn)

<table>
<thead>
<tr>
<th>API</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>TAF</td>
<td>7.9</td>
</tr>
<tr>
<td>TDF</td>
<td>15.8</td>
</tr>
<tr>
<td>AZT</td>
<td>2.2</td>
</tr>
<tr>
<td>NVP</td>
<td>0.0</td>
</tr>
<tr>
<td>EFV</td>
<td>10.0</td>
</tr>
<tr>
<td>LPV</td>
<td>0.9</td>
</tr>
<tr>
<td>ATV</td>
<td>2.3</td>
</tr>
<tr>
<td>DRV</td>
<td>0.5</td>
</tr>
<tr>
<td>DTG</td>
<td>14.8</td>
</tr>
<tr>
<td>RAL</td>
<td>0.1</td>
</tr>
</tbody>
</table>

API for all formulations included
FORECAST FOR PAEDIATRIC USE
High Level Assumptions

• Date of introduction in market (either originator or generic):
  • DTG 50mg and FDCs: 2018
  • TAF FDCs: 2020

• Price:
  • At launch, DTG & TAF priced at par with EFV & TDF respectively
  • Future pricing based on historical price erosion trends

• Positive study results for DTG and TAF in children

• WHO guidelines recommend new products first as alternate and then as preferred regimens

• New products placed on national guidelines within one year from WHO guidelines
Millions of Children Treated in WHO/MPP* forecasts

*WHO/MPP assumes total PLHIV treated per UNAIDS fast track report
Abacavir is clearly the preferred NRTI for use in children, the increasing use of which is attributed to its being the preferred backbone with EFV as well as LPV.

- This could be true for DTG as well particularly if an FDC of ABC/3TC/DTG becomes available.

- Use of AZT declines as a result.

- We do not project uptake of TDF due to toxicity concerns and lack of appropriate formulations.

- There may be low use of TAF in the early years pending clinical validation.
Percentage of children on **first line** treatment using NNRTI, PI and INSTIs

- Since NVP is an alternate as per current WHO Guidelines, it is estimated to decline to zero by 2021
- EFV being the preferred drug in first line for >3y, increases in the first few years, later declining to be replaced by DTG in children >3y from 2018
- LPV, currently preferred for <3y, will also be replaced by DTG from 2020 onward
- DTG
  - Will start being used in children 6-12y once generics are made available by 2018
  - Will replace EFV in children >3y starting 2018, with availability of generics and
  - Will replace LPV in children <3y once data is available by 2020
Percentage of children on **second line** treatment using NRTIs

- In second-line treatment, we assume an increased use of AZT, since most children would be using ABC in first line
- However, once ABC is available as an FDC with DTG, there will be a stability in its market share as is seen from 2020 onwards
- For TDF, we already see it being used in 27% patients in the last ARV Use Survey. This trend would be likely to continue, though at a stable rate
  - We assume a very limited role of TAF in second line for children due to non-availability of data
Percentage of children on second line treatment using NNRTI, PI and INSTI

- Limited use of EFV, which is assumed to decline to zero by 2020
- All children failing NRTIs in first line would move to PI in second line. We have assumed most of these children would move to LPV and some to ATV
- Children failing LPV in first line would move mainly to RAL, but those which are now >3y could also move to DTG
- One thing to note here is that as in case of WHO guidelines for adults, we assume DTG would not be recommended in 2nd line for children. However, in the future some patients failing LPV when older than 3 years may move to DTG instead of RAL
ARV use in 2020 and 2025 - Million Children by Active Ingredient

### Graph Description

The graph illustrates the number of children on ARV therapy in 2020 and 2025, categorized by active ingredient. The y-axis represents the number of children (in millions), while the x-axis lists various ARV drugs: TAF, TDF, AZT, ABC, NVP, EFV, LPV, ATV, DRV, DTG, and RAL.

- **TAF**: No data available for 2020 and 2025.
- **TDF**: No data available for 2020 and 2025.
- **AZT**: No data available for 2020 and 2025.
- **ABC**: No data available for 2020 and 2025.
- **NVP**: No data available for 2020 and 2025.
- **EFV**: 0.2 million in 2020, 0.1 million in 2025.
- **LPV**: 0.4 million in 2020, 0.1 million in 2025.
- **ATV**: No data available for 2020 and 2025.
- **DRV**: No data available for 2020 and 2025.
- **DTG**: 0.1 million in 2020, 0.2 million in 2025.
- **RAL**: No data available for 2020 and 2025.

**API for all formulations included**

---

**World Health Organization**

**medicines patent pool**
Conclusion

- Our forecasts include a mix of judgement and data.
- Areas of convergence are useful to inform action.
- New ARVs represent potential business opportunities for manufacturers.
- Meanwhile, manufacture of existing products such as TDF and EFV would need to be ramped up to meet the growing demand due to higher number of patients forecasted to be on treatment.
Acknowledgements

- Marco Vitoria, World Health Organization
- Martina Penazzato, World Health Organization
- Vincent Habiyambere, World Health Organization
- Boniface Dongmo, World Health Organization
- Sandeep Juneja, Medicines Patent Pool
- Fernando Pascual, Medicines Patent Pool
- Peter Ghys, UNAIDS
- Carlos Passarelli, UNAIDS
- John Stover, Avenir Health
Thank You

Aastha Gupta

agupta@medicinespatentpool.org